Global Epigenetics Market, By Product (Enzymes, Instruments and Consumables, Kits, and Reagents), Application (Oncology and Non-Oncology), Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification, and Chromatin structures), End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, and Contract Research Organizations (CROs)) – Industry Trends and Forecast to 2031.
Epigenetics Market Analysis and Size
The epigenetics market is experiencing exponential growth fueled by advancements in technology. The latest methods, such as CRISPR-based epigenome editing, are revolutionizing research and applications. These breakthroughs enable precise manipulation of gene expression, offering unprecedented insights into diseases, aging, and personalized medicine. As demand surges for innovative solutions, the epigenetics market is poised for substantial expansion and transformative impact.
The global epigenetics market size was valued at USD 15.83 billion in 2023, is projected to reach USD 68.98 billion by 2031, with a CAGR of 20.20% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Enzymes, Instruments and Consumables, Kits, and Reagents), Application (Oncology and Non-Oncology), Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification, and Chromatin structures), End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, and Contract Research Organizations (CROs))
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Bio-Techne (U.S.), Promega Corporation (U.S.), GeneTex, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Illumina, Inc. (U.S.), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd. (Japan), Novartis AG (Switzerland), Abcam Limited (U.K.), Diagenode s.a. (U.S.), Active Motif, Inc. (U.S.), Zymo Research Corporation. (U.S.), Thermo Fisher Scientific Inc. (U.S.), cellcentric (Germany), Syndax Pharmaceuticals (U.S.), New England Biolabs (U.S.), Epizyme, Inc. (U.S.), Domainex (U.K.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), AsisChem Inc. (U.S.), Enzo Life Sciences, Inc. (U.S.), EpiGentek Group Inc. (U.S.), and BioVision Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Epigenetics is the study of changes in gene activity that don't involve alterations to the genetic code itself. These changes can be influenced by various factors such as environment, lifestyle, and experiences. They can impact gene expression and, consequently, traits and health outcomes. Understanding epigenetics is crucial for unraveling complex interactions between nature and nurture in shaping an organism's development and susceptibility to diseases.
Epigenetics Market Dynamics
Drivers
- Increasing Drug Discovery and Development
The recognition of epigenetic modifications as viable targets for drug discovery is propelling market growth. Pharmaceutical firms are heavily investing in epigenetic research to develop groundbreaking therapies. For instance, in cancer treatment, drugs such as Azacitidine and Decitabine, which target DNA methylation, have revolutionized therapy options, demonstrating the market's potential. Similarly, research into epigenetic therapies for neurological disorders and autoimmune diseases is accelerating, further driving market expansion.
- Integration with Other Omics Technologies
The integration of epigenetics with other omics technologies, such as genomics and proteomics, enhances our understanding of biological systems. This synergy fuels demand for multi-omics platforms, driving market growth. For instance, combining epigenetic data with genomic and transcriptomic data enables researchers to elucidate complex gene regulatory networks, leading to breakthroughs in disease understanding and drug development, further propelling the market forward.
Opportunities
- Increasing Cancer Research
Epigenetics plays a crucial role in cancer development and progression. As cancer research advances, there's a growing emphasis on understanding epigenetic modifications, such as DNA methylation and histone modifications, linked to various cancers. This drives demand for epigenetic analysis tools and technologies. For instance, companies such as Illumina and Thermo Fisher Scientific are developing advanced assays and sequencing technologies to meet the increasing need for precise epigenetic analysis in cancer research.
- Rising Personalized Medicine and Drug Development
Epigenetic profiling enables personalized medicine by tailoring treatments to an individual's unique epigenetic profile. This approach is crucial in developing targeted therapies and drug discovery, driving the adoption of epigenetic technologies by pharmaceutical and biotechnology companies. For instance, in oncology, epigenetic markers guide the creation of precise cancer treatments, improving efficacy and patient outcomes. This increasing focus on personalized therapies significantly propels the epigenetics market forward.
Restraints/Challenges
- High Cost of Research and Development
The high cost of research and development in epigenetics significantly hampers the market. Advanced technologies and methodologies require substantial investment, making it expensive for companies to conduct research and develop new products. This financial burden limits the entry of new players and restricts the pace of innovation and commercialization in the epigenetics market.
- Shortage of Skilled Professionals
The epigenetics market is constrained by a significant shortage of skilled professionals. This deficiency hampers the pace of research and development, as there are insufficient experts to advance studies and innovate in the field. The lack of adequately trained personnel limits the industry's capacity to explore and utilize the full potential of epigenetic technologies and therapies.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2023, BioLabs and Promega expanded their collaborative efforts to drive global innovation in life sciences by supporting early-stage startups. Promega GmbH, the German subsidiary of the global life sciences manufacturer, located in Walldorf, now provides advanced equipment, comprehensive services, and specialized training to BioLabs Heidelberg, enhancing their capacity to nurture emerging biotech ventures
- In November 2023, QIAGEN and Element Biosciences, Inc. entered a strategic partnership to deliver comprehensive next-generation sequencing (NGS) workflows for the innovative Element AVITI System. This collaboration aims to enhance the capabilities of NGS applications, offering robust solutions for genomics research and clinical diagnostics, thereby accelerating advancements in the field of molecular biology
- In October 2023, Zenith Epigenetics Ltd. and Cencora agreed to commercialize the ZEN-3694 program, an epigenetic therapy designed to enhance the efficacy of existing cancer treatments. This partnership seeks to leverage the synergistic potential of ZEN-3694 to improve patient outcomes by integrating it with currently marketed oncology drugs, offering a promising approach to cancer therapy
- In February 2022, Zenith Epigenetics Ltd. announced the dosing of the first patient in a clinical trial combining ZEN-3694, a BET inhibitor, with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitors, OPDIVO and YERVOY. Sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, this trial focuses on treating solid tumor cancers through innovative combination therapies
- In February 2022, Element Biosciences, Inc., the developer of a revolutionary DNA sequencing platform, partnered with Dovetail Genomics to showcase the efficacy and performance of Dovetail’s proximity ligation-based next-generation sequencing (NGS) library preparation solutions on Element’s AVITI System. This collaboration aims to demonstrate the superior capabilities of their integrated technologies in advancing genomic research
Epigenetics Market Scope
The market is segmented on the basis of product, application, technology, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Enzymes
- Instruments and Consumables
- Kits
- ChIP sequencing kit
- Whole Genomic Amplification kit
- Bisulfite Conversion kit
- RNA sequencing kit
- Others
- Reagents
Application
- Oncology
- Solid Tumors
- Liquid Tumors
- Non-Oncology
- Inflammatory Diseases
- Metabolic Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others
Technology
- DNA Methylation
- Histone Methylation
- Histone Acetylation
- Large non-coding RNA
- MicroRNA modification
- Chromatin structures
End User
- Academic and Research Institutes
- Pharmaceutical Companies and Biotechnology Companies
- Contract Research Organizations (CROs)
Epigenetics Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, product, application, technology, and end user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to be the fastest-growing region in the epigenetics market due to rising disposable incomes. Additionally, the increasing unmet clinical needs of patients are anticipated to further propel market growth, fostering advancements and adoption of epigenetic solutions across the region.
North America is expected to dominate the epigenetics market due to increasing research activities and innovative healthcare amenities. Continuous advancements in diagnostic processes further boost market growth in the region, positioning it as a leader in epigenetic research and applications during the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Epigenetics Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Bio-Techne (U.S.)
- Promega Corporation (U.S.)
- GeneTex, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Eisai Co., Ltd. (Japan)
- Novartis AG (Switzerland)
- Abcam Limited (U.K.)
- Diagenode s.a. (U.S.)
- Active Motif, Inc. (U.S.)
- Zymo Research Corporation. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- cellcentric (Germany)
- Syndax Pharmaceuticals (U.S.)
- New England Biolabs (U.S.)
- Epizyme, Inc. (U.S.)
- Domainex (U.K.)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- AsisChem Inc. (U.S.)
- Enzo Life Sciences, Inc. (U.S.)
- EpiGentek Group Inc. (U.S.)
- BioVision Inc. (U.S.)
SKU-